1. Home
  2. RDNW vs ALXO Comparison

RDNW vs ALXO Comparison

Compare RDNW & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RideNow Group Inc.

RDNW

RideNow Group Inc.

HOLD

Current Price

$6.43

Market Cap

250.8M

Sector

Technology

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.95

Market Cap

205.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDNW
ALXO
Founded
2013
2015
Country
United States
United States
Employees
1906
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
250.8M
205.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
RDNW
ALXO
Price
$6.43
$1.95
Analyst Decision
Hold
Strong Buy
Analyst Count
2
4
Target Price
$6.50
$3.50
AVG Volume (30 Days)
67.5K
858.8K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
26.36
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$9.01
N/A
Revenue Next Year
$6.53
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.98
$0.51
52 Week High
$8.55
$2.66

Technical Indicators

Market Signals
Indicator
RDNW
ALXO
Relative Strength Index (RSI) 55.58 47.99
Support Level $6.28 $1.42
Resistance Level $7.22 $2.31
Average True Range (ATR) 0.33 0.15
MACD 0.12 -0.02
Stochastic Oscillator 82.10 18.18

Price Performance

Historical Comparison
RDNW
ALXO

About RDNW RideNow Group Inc.

RideNow Group Inc operates solely as a powersports dealership group. Its offerings include new and pre-owned vehicles such as motorcycles, all-terrain vehicles (ATVs), side-by-side vehicles (SXS), and personal watercraft (PWC). It also sells parts, apparel, and accessories, and provides financing, insurance, and aftermarket products, along with repair and maintenance services. The majority of the company's revenue is derived from powersports vehicle sales, and the rest from parts, service and accessories/merchandise, and finance and insurance products.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: